Mephentermine

Summary

Mephentermine (CHEMBL1201234) is an approved small molecule (ATC C01CA11); indicated across 1 condition including cardiovascular disorder.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: C01CA11
• Indications: 1 condition
• Clinical trials: 1
• Chemistry: 163.26 Da · C11H17N

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1201234
Name	Mephentermine
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	3677
ATC	C01CA11
Molecular formula	C11H17N
Molecular weight	163.26
InChIKey	RXQCGGRTAILOIN-UHFFFAOYSA-N

SMILES: CC(C)(CC1=CC=CC=C1)NC

IUPAC name: N,2-dimethyl-1-phenylpropan-2-amine

Also known as: Mefentermina, Mephentermine, SID11112475, MEPHENTERMINE, MEPHENTERMINE SULFATE

Parent form; salt/anhydrous children: CHEMBL1200996, CHEMBL3184799

Patent coverage: 571 distinct patent families (1,985 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 3 (assay-derived). Sample: Prelamin-A/C, Ferritin light chain, Cytochrome P450 2D6.

Bioactivity

ChEMBL activities: 4 potent at pChembl ≥ 5 of 4 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
LMNA	8.49	Potency	3.2	nM	CHEMBL_ACT_3664143
P02791	6.25	Potency	562.3	nM	CHEMBL_ACT_4496898
CYP2D6	5	Potency	10000	nM	CHEMBL_ACT_4998330
CYP2D6	5	AC50	10000	nM	CHEMBL_ACT_6010950

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 indication (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
cardiovascular disorder	4	MONDO:0004995	EFO:0000319

Clinical trials

Total trials: 1.

Phase distribution

Phase	Trials
PHASE3	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT05706727	PHASE3	COMPLETED	Comparative Analytical Study of Intravenous Bolus Dose of Mephentermine and Phenylephrine for Hemodynamic Stability During Elective Cesarean Section Under Spinal Anesthesia at KIST Medical College and Teaching Hospital

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).